All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
The future of JAK inhibition in myelofibrosis
Bookmark this article
During the last steering committee (SC) meeting that was held on April 20, 2022, the SC members discussed about the future of JAK inhibition in myelofibrosis. The session was chaired by John Mascarenhas and involved an analysis from Claire Harrison, Haifa Kathrin Al-Ali, Tiziano Barbui, Jean-Jacques Kiladjian, and Stefan N. Constantinescu.
The future of JAK inhibition in myelofibrosis
Key topics of discussion included: “How to select appropriate JAK inhibitors in patients with myelofibrosis (MF)”; “What patient subsets a JAK inhibitor may capture”; and “The future of JAK inhibitors in treating myelofibrosis, and whether this type of inhibitor will exist as a single agent or in combination therapy at initiation.
More about...
Your opinion matters
19 votes - 79 days left ...
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox